Subscribe to RSS
DOI: 10.1055/s-0031-1286343
No Correlation between Lithium Serum Levels and Psychopathological Features during the Euthymic Interval of Patients with Recurrent Affective Disorder
Publication History
received 10 April 2011
revised 04 July 2011
accepted 29 July 2011
Publication Date:
11 October 2011 (online)
![](https://www.thieme-connect.de/media/pharmaco/201201/lookinside/thumbnails/10.1055-s-0031-1286343-1.jpg)
Abstract
Introduction:
The aim of this prospective study was to investigate the influence of lithium serum levels on subclinical psychopathological features during the euthymic interval in patients with an affective disorder.
Methods:
The study included 54 patients with a recurrent affective disorder undergoing a continuous prophylactic lithium treatment (31 unipolar, 23 bipolar). The observation period lasted for 2 years and included 332 visits. Visits consisted of a detailed interview, a continuous measurement of lithium levels and the collection of validated scales including HAMD, YMRS, CGI, VAMS and the SCL-90R. Several correlations between lithium serum levels and different psychopathological features during the euthymic interval were calculated on an individual patient basis and on a group basis to reveal generally occurring correlations.
Results:
No generally occurring significant correlations between lithium serum levels and specific psychopathological features were found. Only on a single patient level, 32 significant correlations between lithium level and specific psychopathological features were found, partly indicating a negative and partly indicating a positive influence of higher lithium levels on psychopathological symptoms. Nevertheless, in the group analyses no significant correlations were found.
Discussion:
Higher lithium levels were not associated with an improved psychopathological status, but they were not associated with a worse status (due to a higher burden of side effects) either. According to the literature there is currently no strong evidence to treat patients with a higher lithium level. It is recommended to start with a lower level and to continue with individual adjustments in accordance to prophylactic efficacy and tolerability.
-
References
- 1 Müller-Oerlinghausen B. Does effective lithium prophylaxis result in a symptom-free state of manic-depressive illness? Some thoughts on the fine-tuning of mood stabilization. Compr Psychiatry 2000; 41: 26-31
- 2 Bschor T. Therapy-resistant depression. Expert Rev Neurother 2010; 10: 77-86
- 3 Bschor T, Adli M. Treatment of depressive disorders. Dtsch Arztebl Int 2008; 105: 782-792
- 4 Goodnick PJ, Fieve RR, Peselow ED et al. General behaviour inventory: measurement of subclinical changes during depression and lithium prophylaxis. Acta Psychiatr Scand 1985; 73: 529-532
- 5 Bauer M, Glenn T, Grof P et al. Subsyndromal mood symptoms: a useful concept for maintenance studies of bipolar disorder?. Psychopathology 2010; 43: 1-7
- 6 Goodnick PJ, Fieve RR, Schlegel A et al. Predictors of interepisode functioning and relapse in affective disorder patients treated with lithium carbonate. Am J Psychiatry 1987; 144: 367-369
- 7 Goodnick PJ, Fieve RR, Schlege A et al. Inter-episode major and subclinical symptoms in affective disorder. Acta Psychiatr Scand 1987; 75: 597-600
- 8 Pintor L, Gasto C, Navarro V et al. Relapse of major depression after complete and partial remission during a 2-year follow-up. J Affect Disord 2003; 73: 237-244
- 9 Pintor L, Torres X, Navarro V et al. Is the type of remission after a major depressive episode an important risk factor to relapses in a 4-year follow-up. J Affect Disord 2004; 82: 291-296
- 10 Kennedy N, Paykel ES. Residual symptoms at remission from depression: impact on long-term outcome. J Affect Disord 2004; 80: 135-144
- 11 Fava GA. Subclinical symptoms in mood disorders: pathophysiological and therapeutic implications. Psychol Med 1999; 29: 47-61
- 12 Morriss R. Clinical importance of inter-episode symptoms in patients with bipolar affective disorder. J Affect Disord 2002; 72: 3-13
- 13 Bauer M, Grof P, Müller-Oerlinghausen B. (eds.). Lithium in neuropsychiatry. The comprehensive guide. Informa healthcare. London:
- 14 Maj M, Starace F, Nolfe G et al. Minimum plasma lithium levels required for effective prophylaxis in DSM III bipolar disorder: a prospective study. Pharmacopsychiatry 1986; 19: 420-423
- 15 Keller MB, Lavori PW, Kane JM et al. Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium. Arch Gen Psychiatry 1992; 49: 371-376
- 16 Severus WE, Lipkovich IA, Licht RW et al. In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005. Eur Psychiatry 2010 ; ; 443-449
- 17 Severus WE, Kleindienst N, Seemüller F et al. What is the optimal serum lithium level in the long-term treatment of bipolar disorder − a review?. Bipolar Disord 2008; 10: 231-237
- 18 Severus WE, Kleindienst N, Evoniuk G et al. Is the polarity of relapse/recurrence in bipolar-I disorder patients related to serum lithium levels? Results from an empirical study. J Affect Disord 2009; 115: 466-470
- 19 Goodnick PJ, Fieve RR. Plasma lithium level and interepisode functioning in bipolar disorder. Am J Psychiatry 1985; 142: 761-762
- 20 Solomon DA, Ristow WR, Keller MB et al. Serum lithium levels and psychosocial function in patients with bipolar I disorder. Am J Psychiatry 1996; 153: 1301-1307
- 21 Müller-Oerlinghausen B. Psychological effects, compliance and response to long-term lithium. Br J Psychiatry 1982; 141: 411-419
- 22 Wingo AP, Winge TS, Harvey PD et al. Effects of lithium on cognitive performance: a meta-analysis. J Clin Psychiatry 2009; 70: 1588-1597
- 23 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
- 24 Young RC, Biggs JT, Ziegler VE et al. A rating scale for mania: reliability, validity, sensitivity. Br J Psychiatry 1978; 133: 429-435
- 25 Guy W. ed. ECDEU Assessment Manual for Psychopharmacology. Rev. Rockville, Clinical global impressions, National Institute of Mental Health, Early Clinical Drug Evaluation. Psychopharmacology Research Branch. 1976: 217-222
- 26 Nyenhuis DL, Stern RA, Yamamoto C et al. Standardization and validation of the visual analog mood scales. Clin Neuropsychologist 1997; 11: 407-415
- 27 Stern RA. Visual analog mood scales. Psychological Assessment Resources, Inc; Odessa [FL]: 1997
- 28 Derogatis LR, Lipman R, Covi L. The SCL-90: an outpatient psychiatric rating scale. Psychopharmacol Bull 1973; 9: 13-28
- 29 Derogatis LR, Cleary PA. Confirmation of the dimensional structure of the SCL-90: a study in construct validation. J Clin Psychology 1977; 33: 981-989
- 30 Barker DG. Averaging correlation coefficients: a basic program. Educ Psychol Meas 1990; 50: 843-844
- 31 Bauer M, Bschor T, Pfennig A et al. WFSBP Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry [WFSBP] Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007; 8: 67-104
- 32 Grunze H, Kasper S, Goodwin G et al. WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry [WFSBP] guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry 2004; 5: 120-135
- 33 Baldessarini RJ, Tondo L. Suicidal risks during treatment of bipolar disorder patients with lithium versus anticonvulsants. Pharmacopsychiatry 2009; 42: 72-75